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Background: There are few data concerning the impact of inflammatory polyarthritis (IP) on quantitative heel
ultrasound (QUS) measurements. The aims of this analysis were i) to determine the influence of IP on QUS
measurements at the heel and, ii) among those with IP to determine the influence of disease related factors on
these measurements.
Methods: Men and women aged 16 years and over with recent onset IP were recruited to the Norfolk Arthritis
Register (NOAR). Individuals with an onset of joint symptoms between 1989 and 1999 were included in this
analysis. At the baseline visit subjects underwent a standardised interview and clinical examination with blood
taken for rheumatoid factor. A population-based prospective study of chronic disease (EPIC-Norfolk) independently
recruited men and women aged 40 to 79 years from the same geographic area between 1993 and 1997. At a
follow up assessment between 1998 and 2000 subjects in EPIC-Norfolk were invited to have quantitative ultrasound
measurements of the heel (CUBA-Clinical) performed. We compared speed of sound (SOS) and broadband
ultrasound attenuation (BUA), in those subjects recruited to NOAR who had ultrasound measurements performed
(as part of EPIC-Norfolk) subsequent to the onset of joint symptoms with a group of age and sex matched non-IP
controls who had participated in EPIC-Norfolk. Fixed effect linear regression was used to explore the influence of IP
on the heel ultrasound parameters (SOS and BUA) so the association could be quantified as the mean difference in
BUA and SOS between cases and controls. In those with IP, linear regression was used to examine the association
between these parameters and disease related factors.
Results: 139 men and women with IP and 278 controls (mean age 63.2 years) were studied. Among those with IP,
mean BUA was 76.3 dB/MHz and SOS 1621.8 m/s. SOS was lower among those with IP than the controls
(difference =−10.0; 95% confidence interval (CI) –17.4, -2.6) though BUA was similar (difference =−1.2; 95% CI −4.5,
+2.1). The difference in SOS persisted after adjusting for body mass index and steroid use. Among those with IP,
disease activity as determined by the number of swollen joints at baseline, was associated with a lower SOS. In
addition SOS was lower in the subgroup that satisfied the 1987 ACR criteria. By contrast, disease duration, steroid
use and HAQ score were not associated with either BUA or SOS.
Conclusions: In this general population derived cohort of individuals with inflammatory polyarthritis there is
evidence from ultrasound of a potentially adverse effect on the skeleton. The effect appears more marked in those
with active disease.* Correspondence: stephen.pye@manchester.ac.uk
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Rheumatoid arthritis (RA) is associated with an
increased risk of both hip and vertebral fracture [1-8].
Data from clinic based and population studies suggest
that bone mass is reduced in subjects with RA compared
with non-RA controls which may in part explain this
increased risk [9-14]. Quantitative heel ultrasound mea-
surements including speed of sound (SOS) and broad-
band attenuation (BUA) have been shown to be
associated with risk of spine and non spine fracture in
men and women [15-21]. There is some evidence that
patients with RA have a reduction in heel ultrasound
parameters compared to non RA controls [22-30]. Most
of these studies though include patients who were
recruited from secondary care and therefore likely to
have more severe and longer duration of disease. Fur-
thermore there are few data in the literature concerning
the influence of disease activity related factors on heel
ultrasound parameters in individuals with inflammatory
arthritis [22,24-29,31]. We therefore studied a group of
men and women recruited to the Norfolk Arthritis
Register, a unique primary care based cohort of men and
women with new onset inflammatory polyarthritis in
which information about disease activity is recorded in a
standardised fashion and an appropriately derived com-
parison group. The aim of this analysis was i) to deter-
mine the influence of IP on SOS and BUA as measured
using heel ultrasound and, ii) among those with IP to




Subjects with IP and non-IP controls were recruited
from the same population source: the Norfolk cohort of
the European Prospective Investigation of Cancer (EPIC-
Norfolk). Cases were individuals with inflammatory
polyarthritis (IP) notified to the Norfolk Arthritis Regis-
ter (NOAR) and who had also subsequently participated
in EPIC. Two controls (age and sex matched) were
selected for each case, being subjects who had been
recruited to EPIC-Norfolk and who were not registered
with NOAR. To determine the influence of IP on SOS
and BUA, we compared these measurements between
the cases and matched controls. To determine the influ-
ence of disease activity variables on these parameters we
restricted our analysis to just the subjects with IP. Both
EPIC-Norfolk and NOAR were in compliance with the
Helsinki Declaration and approved by the ethics com-
mittee of the Norwich District Health Authority.
Norfolk Arthritis Register (NOAR)
NOAR is a primary care based inception cohort of
adults aged 16 years and over, registered with a local GP,with early IP in the former Norfolk Health Authority
(UK). Subjects are included in the register if they had 2
or more swollen joints for a period of at least 4 weeks,
with onset since January 1, 1989. Detailed methods for
the study have been published previously [32]. The
current analysis includes subjects with an onset of symp-
toms before 2000. At baseline, subjects completed an
interviewer administered questionnaire and Health As-
sessment Questionnaire [33]. They were examined by a
trained nurse for the presence of tender and swollen
joints (51 joints), and had blood taken for rheumatoid
factor measurement. As explained elsewhere, subjects
had x-rays of the hands and feet performed if they satis-
fied the ACR criteria for RA or if the presence of ero-
sions would make them satisfy these criteria [34]. The
ACR criteria were applied at the baseline visit.
European Prospective Investigation of Cancer
(EPIC-Norfolk)
Subjects were recruited in Norfolk, UK for participation
in the European Prospective Investigation of Cancer – a
large multicentre population based study with the pri-
mary aim of establishing the relationship between diet
and the risk of developing cancer. In Norfolk, approxi-
mately 25,000 men and women aged 40–79 years were
recruited between 1993 and 1997. Subjects completed a
health questionnaire which included information about
steroid therapy for 3 or more months. Height and weight
were measured in light clothing without shoes. Body
mass index (BMI) was calculated using measurements
made at the baseline EPIC visit by dividing weight (Kg)
by height squared (m2). Detailed methods have been
published previously [35].
Calcaneal ultrasound
In 1998–2000 men and women from EPIC, now aged 42
to 82 years, were invited to attend a second visit where
measurements of QUS of the heel were conducted by
trained nurses working to standard protocols. Both
speed of sound (SOS) and broadband ultrasound attenu-
ation (BUA) were recorded for each subject. Measure-
ment was made using a CUBA sonometer (McCue
Ultrasonics, Winchester) at least twice on each foot. The
mean of the measures (left and right foot) were used for
analysis. The coefficient of variation was 3.5% [16]. Five
CUBA machines were used and each was calibrated daily
with its physical phantom. A roving physical phantom
was used monthly to check calibration between
machines and room temperature measured daily.
Analysis
For each individual notified to NOAR who had had heel
ultrasound measurements performed, two age and sex
matched controls were selected from EPIC-Norfolk. The
Table 2 Disease characteristics of subjects with IP at
baseline
Variable Men N=52 Women N=87
Mean (SD) Mean (SD)
Duration of arthritis* (years) 4.8 (2.9) 5.6 (2.8)
Median (IQR) Median (IQR)
Number of swollen joints 2.0 (1.0, 8.0) 5.0 (2.0, 11.0)
Number of tender joints 5.0 (2.0, 8.5) 6.0 (2.0, 15.0)
Number of both swollen
and tender joints
1.0 (0.0, 3.5) 2.0 (0.0, 5.0)
Larsen score1 27.5 (13.0,31.0) 11.0 (1.0, 21.0)
HAQ score (0–3) 0.5 (0.1, 1.1) 0.8 (0.4, 1.3)
% %
Rheumatoid factor + ve 39.1 33.8
Erosions1 75.0 56.5
Satisfied ARA RA criteria (4/7 definition) 22.9 45.8
Satisfied ARA RA criteria (tree definition) 41.7 60.2
Steroid use for at least 3 months 5.8 17.2
*Years between first symptom onset and ultrasound scan.
1Assessed in those with baseline radiographs (n = 27).
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fect linear regression was used to look at the association
between heel ultrasound measurement and case status,
with the bone ultrasound parameter (SOS or BUA) as
the outcome and case status as the independent variable.
As our aim was to examine the influence of IP on bone
health, this approach allowed us to quantify the associ-
ation in terms of the mean absolute difference (and 95%
confidence interval) in the bone ultrasound parameters
between the cases and controls which we felt was easy
to interpret. Adjustments were subsequently made for
body mass index and also steroid therapy (as assessed in
EPIC-Norfolk). In the second stage we used simple lin-
ear regression to examine the influence of the following
disease related factors assessed at baseline on the ultra-
sound parameters : swollen and tender joint count,
HAQ, rheumatoid factor, and whether the subject satis-
fied the 1987 ACR criteria at baseline (both the trad-
itional four of seven criteria and the decision tree
approach [34] and the disease duration as determined
from the time of symptom onset until the ultrasound
scan, after adjustment for age and sex [34]. For the pur-
poses of analysis, the joint counts were categorised into
tertiles, the lowest tertile representing those with the
least number of involved joints. The results were
expressed as β coefficients and 95% confidence intervals
(CI). Having determined the disease related predictors of
the heel ultrasound parameters, we then used fixed ef-
fect linear regression to determine whether or not these
explained differences between those with IP and the non
IP controls. Statistical analysis was performed using
STATA (Stata Corporation. Stata Statistical Software: Re-
lease 9.2, College Station, TX, USA, 2008).
Results
Subject characteristics
In all, 139 subjects (52 men and 87 women) with IP and
278 age and sex matched controls were studied. The
characteristics of these subjects are presented in Table 1.
Women with IP had a slightly greater BMI (26.9 kg/m2
vs 25.6 kg/m2) and (as expected) a higher prevalence of





Age at interview (years) 65.7 (8.1)
Body mass index at baseline (kg/m2) 26.9 (3.4) 26.6
%
Steroid tablets/injections for at least 3 months 5.8 4
IP = inflammatory polyarthritis.In men, there were no differences between those with
and without IP with respect to body mass index or ster-
oid use.
Disease related characteristics at baseline are pre-
sented in Table 2. The mean duration of disease from
symptom onset to time of ultrasound was 4.8 years
(standard deviation [SD] = 2.9) in men and 5.6 years
(SD= 2.8) in women (mean duration of symptoms prior
to baseline assessment in NOAR was 0.9 years (SD= 1.1)
in men and 1.3 years (SD= 1.9) in women). In terms of
joint involvement, men had a median of 1.0 (interquar-
tile range [IQR] = 0.0,3.5) and women a median of 2.0
(IQR= 0.0, 5.0) joints that were both swollen and tender.
The median HAQ score was 0.5 (IQR= 0.1, 1.1) in men
and 0.8 (IQR= 0.4, 1.3) in women. 39% of men and 34%
of women were rheumatoid factor positive and 42% and
60% respectively satisfied the ACR criteria for rheuma-
toid arthritis using the tree definition. Given the design
(see methods) only 27 subjects had hand radiographs atWomen
n-IP IP Non-IP
104 N=87 N=174
n (SD) p value mean (SD) mean (SD) p value
61.7 (9.0)
(3.4) 0.68 26.9 (4.3) 25.6 (4.0) 0.02
% % %
.8 0.80 17.2 1.7 <0.001
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evidence of erosive disease.
Influence of IP on SOS and BUA
Overall, mean SOS was 1621.8 m/s (SD= 43.4) and BUA
was 76.3 dB/MHz (SD= 18.4) in those with IP (Table 3).
Mean SOS was lower in those with IP than the controls
for both men (1629.0 vs 1644.0 m/s) and women (1617.6
vs 1624.5 m/s) though the difference was statistically sig-
nificant for men only. There was no difference in BUA
between those with IP and their matched controls in
men or women. There was no evidence of interaction
between sex and case status, BMI or steroid use and in
subsequent analysis the data for men and women were
pooled. Using fixed effect linear regression, with the
bone ultrasound parameter as the dependent variable
and case status as the independent variable, SOS was
lower among those with IP than the matched controls
(difference −10.0; 95%CI −17.4, -2.6), a difference of
0.6%, see Table 4. This difference persisted after adjust-
ing for body mass index and steroid use (difference −9.6;
95%CI −17.9, -1.3). BUA, however, was similar between
those with IP and controls (difference −1.2; 95%CI −4.5,
2.1). When the analysis was restricted to those who ful-
filled the ACR tree criteria at baseline the differences be-
tween those with IP and the controls became more
marked for both SOS (difference =−17.3; 95% CI −28.8,
-5.7) and for BUA, which now became statistically sig-
nificant (difference =−7.2;95% CI −12.4, -2.1). Higher
BMI at baseline was associated with a higher BUA (β co-
efficient 1.1; 95%CI 0.6, 1.6) independent of case status.
BMI and steroid use were not independently associated
with SOS, see Table 4.
Influence of disease related factors on SOS and BUA
The influence of disease related factors on ultrasound
parameters is presented in Table 5. After adjusting for
age and sex, compared to those in the lowest tertile of
swollen and tender joint counts, those in the mid and
upper tertile had lower BUA though this was significant
for the middle tertile only (difference =−6.4; 95%CI
−12.7, -0.2). Compared to those who did not satisfy the
ACR criteria (either list or tree definition) those that did





Broadband ultrasound attenuation (dB/MHz) 85.8 (18.1) 91.1 (
Speed of sound (m/s) 1629.0 (47.6) 1644.0
IP = inflammatory polyarthritis.95%CI −13.7, -3.2 using the tree definition). With re-
spect to SOS, compared to those in the lowest tertile of
swollen joint count, those in the mid and upper tertiles
had a lower SOS which was significant for the upper ter-
tile (difference =−20.1; 95%CI −35.6, -4.6). There was
evidence also of a significant linear trend for an increase
in both the swollen joint count and swollen and tender
joint count and lower SOS. Compared to those who did
not satisfy the ACR criteria (using either list or tree def-
inition), those that did also had a reduced SOS (differ-
ence =−18.7; 95%CI −32.1, -5.2 using the tree
definition). Larsen score, presence of erosions (in those
who had X-rays performed at baseline), disease duration
(time between symptom onset and the ultrasound scan),
rheumatoid factor and HAQ were not associated with
the ultrasound parameters.
We looked next at whether the swollen joint count as
a marker of inflammation could explain the difference
between cases and controls, assuming that the controls
had no inflamed joints. After adjusting for BMI, steroid
use and number of swollen joints the difference in SOS
between those with and without IP became much
weaker and non significant (difference =−3.9; 95%CI
−14.6, 6.7).Discussion
In this analysis, subjects with IP presenting to primary
care had a modestly but significantly lower SOS though
not BUA compared to population based controls. The
effect was more marked among those who satisfied ACR
criteria at baseline and for these subjects BUA was also
lower than controls. Disease activity as determined by
the swollen joint count explained in part the reduction
in SOS in women with IP.
Our study has several advantages: it was population
based with both cases and controls nested within the
population-derived cohort. It used standard methods in
assessment of both IP and also assessment of heel ultra-
sound. There are though several limitations which need
to be considered when interpreting the results. Not all
patients with an episode of IP in the Norfolk area will
have presented to primary care and among those that do
it is likely that not all will have been referred or notified
to NOAR. Such patients are likely to have less severeWomen
-IP IP Non-IP
04 N=87 N=174
(SD) p value mean (SD) mean (SD) p value
18.6) 0.09 70.6 (16.2) 69.3 (14.7) 0.52
(35.5) 0.03 1617.6 (40.3) 1624.5 (38.9) 0.18
Table 4 Influence of case/control status, body mass index (BMI) and steroid use on ultrasound parameters in men and
women
Broadband attenuation (dB/MHz) Speed of sound (m/s)
Univariatea Multivariateb Univariatea Multivariateb
β coeff (95% Cl) β coeff (95% Cl) β coeff (95% Cl) β coeff (95% Cl)
Case/Control status
control Referent Referent Referent Referent
case −1.2 (−4.5, 2.1) −2.6 (−6.1, 1.0) −10.0 (−17.4, -2.6)* −9.6 (−17.9, -1.3)*
BMI at baseline (kg/m2) 1.1 (0.6, 1.6)* 1.1 (0.6, 1.6)* 0.6 (−0.6, 1.8) 0.8 (−0.4, 2.0)
Steroids ≥3 months
no Referent Referent Referent Referent
yes 6.1 (−1.6, 13.7) 6.8 (−1.7, 15.3) −2.2 (−19.9, 15.5) 1.5 (−18.3, 21.3)
aunadjusted model.
bmodel includes case/control status, BMI at baseline and steroid use.
*p< 0.05.
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study is likely to have missed some subjects with mild
disease. All of the joint assessments were undertaken by
one of a team of trained research nurses which may
have introduced error into measures such as the joint
count. Any imprecision in assessment would tend to at-
tenuate significant biological associations. The ultra-
sound assessments were also undertaken at a variable
duration after the onset of the arthritis. The average
disease duration was short at around 5 years until the
time of the scan, however, duration of disease had no
effect on the results. In this regard it is interesting to
note that a one off baseline joint assessment seemed to
explain most of the difference, albeit quantitatively
small, in SOS between cases and controls. One inter-
pretation of this finding is that any influence of disease
is predicted from the earliest stage. There wasn’t suffi-
cient information to examine the influence of diagnoses
other than RA. There was also no formal assessment of
physical activity at baseline and it was not possible
therefore to look at the effect of this on the bone para-
meters subsequently assessed. Finally, our results relate
to a cohort of European Caucasian men and women liv-
ing in the Norfolk (UK) area, so caution is required in
extrapolation beyond this group.
How do our results compare with previous studies?
Our data in relation to subjects with IP is consistent
with previous studies which suggest a reduction in SOS
among patients with RA (based on ACR criteria) com-
pared to non RA controls though the reduction (0.6%) is
less marked than observed in most of these studies [22-
24,26,28-30]. In contrast to previous studies in RA
patients we found no association between IP and BUA,
though among those subjects in our study who satisfied
the ACR criteria (tree definition) at baseline, BUA was
reduced compared to age matched controls (70.6 vs
77.5 dB/MHz). To our knowledge there are no otherdata concerning the influence of undifferentiated inflam-
matory polyarthritis on heel ultrasound parameters.
Data concerning the impact of disease related variables
on heel ultrasound parameters are somewhat conflicting.
Some, though not all, report an association between
SOS and BUA with disease activity as assessed by ESR,
CRP or swollen/tender joint counts [26-29]. In addition
some reports suggest an association with the HAQ score
[22,24-29,31]. Our data support an association between
disease activity as determined by swollen joint and a
combined swollen and tender joint and SOS. We found
no association, however, with HAQ score and no associ-
ation with other disease related parameters including
disease duration or rheumatoid factor.
Studies in men and women suggest that both SOS and
BUA are important predictors of fracture [15-21]. The
mechanism by which IP might influence these para-
meters is unclear though it is possible that increased
bone turnover perhaps related to increased cytokine pro-
duction in those with active disease may influence bone
[36-38]. Our finding of an association between SOS and
the swollen joint count would be consistent with this.
To date there are no data from prospective studies re-
lating bone ultrasound parameters in RA or IP to frac-
ture risk and therefore the extent to which the results
are clinically relevant is as yet unclear. There is some
evidence from cross-sectional studies that BUA and SOS
are lower in RA patients with vertebral deformity than
those without [25,30]. Prospective studies are, however,
required including assessment of ultrasound, measure-
ment of bone mass and collection of fracture data in
order to determine the clinical relevance of ultrasound
in IP.
Conclusions
In conclusion in this primary-care derived cohort of
patients with inflammatory polyarthritis there is
Table 5 Influence of IP baseline characteristics on ultrasound parameters in men and women
Broadband attenuation Speed of sound
(dB/MHz) (m/s)
β coeff (95% Cl)a β coeff (95% Cl)a
Symptom duration1 (years) 0.3 (−0.7, 1.2) −0.7 (−3.2, 1.7)
Rheumatoid Factor+
no Referent Referent
yes −4.0 (−9.8, 1.9) −4.9 (−19.7, 10.0)
Tertiles of swollen joint count
low Referent Referentb
mid −4.1 (−10.8, 2.7) −6.3 (−23.2, 10.7)
high −6.0 (−12.2, 0.1) −20.1 (−35.6, -4.6)*
Tertiles of tender joint count
low Referent Referent
mid 2.4 (−4.3, 9.1) −4.3 (−21.1, 12.6)
high −1.9 (−8.5, 4.7) −13.3 (−29.9, 3.3)
Tertiles of both swollen & tender joint count
low Referent Referentb
mid −6.4 (−12.7, -0.2)* −13.7 (−29.6, 2.2)
high −5.3 (−12.0, 1.4) −16.1 (−33.1, 0.9)
Larsen score2 0.1 (−0.2, 0.3) −0.1 (−1.0, 0.7)
Erosions2
no Referent Referent
yes 0.9 (−8.3, 10.0) 8.2 (−23.3, 39.7)
Satisfied ARA criteria (4/7 definition)
no Referent Referent
yes −7.8 (−13.4, -2.3)* −18.9 (−33.1, -4.8)*
Satisfied ARA criteria (tree definition)
no Referent Referent
yes −8.5 (−13.7, -3.2)* −18.7 (−32.1, -5.2)*
HAQ score −0.6 (−5.4, 4.3) −2.1 (−14.5, 10.3)
Steroids ≥3 months
no Referent Referent
yes 7.3 (−0.7, 15.3) 9.7 (−11.1, 30.6)
aadjusted for age and sex; bp< 0.05 test for trend; *p< 0.05.
1Years between first symptom onset and ultrasound scan.
2Assessed in those with baseline radiographs (n = 27).
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on the skeleton. The effect appears more marked in
those with active disease.
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